In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 141 to 150 of 372

TitleTypeExpected publication date
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidance
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidanceTBC
Ianalumab for treating active Sjogren's syndrome ID6634Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]Technology appraisal guidanceTBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]Technology appraisal guidanceTBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]Technology appraisal guidanceTBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Implanting a baroreceptor stimulation device for resistant hypertensionInterventional procedures guidanceTBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All